Integra Lifesciences Holdings (IART) Operating Leases (2019 - 2026)

Integra Lifesciences Holdings' Operating Leases history runs 8 years deep, the most recent figure standing at $174.0 million for Q1 2026.

• In Q1 2026, Operating Leases fell 0.91% year-over-year to $174.0 million; the TTM figure through Mar 2026 stood at $174.0 million (down 0.91% YoY), while the FY2025 annual figure was $163.1 million, down 2.32% from the prior year.
• Operating Leases came in at $174.0 million for Q1 2026 at Integra Lifesciences Holdings, up from $163.1 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $186.4 million in Q1 2024 to a low of $87.8 million in Q1 2022.
• A 5-year average of $165.6 million and a median of $167.8 million in 2024 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases decreased 19.77% in 2022 and jumped 95.55% in 2023, its largest moves.
• Integra Lifesciences Holdings' Operating Leases stood at $157.4 million in 2022, then climbed by 5.99% to $166.8 million in 2023, then advanced by 0.05% to $166.9 million in 2024, then declined by 2.32% to $163.1 million in 2025, then rose by 6.74% to $174.0 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $174.0 million, $163.1 million, and $174.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison